Differential association also seen in subgroup analysis of proximal colon cancer<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Feb. 25, 2025 (HealthDay News) — The association of long-term yogurt intake with colorectal cancer incidence seems to differ by the abundance of tumor tissue Bifidobacterium<\/em>, according to a study published online Feb. 12 in Gut Microbes<\/em>.<\/p>\n Satoko Ugai, Ph.D., from Brigham and Women’s Hospital in Boston, and colleagues utilized the prospective cohort incident-tumor biobank method and resources of two prospective cohort studies to examine whether long-term yogurt intake is associated with colorectal cancer incidence differentially by tumor subgroups according to the amount of tissue Bifidobacterium<\/em>.<\/p>\n The researchers documented 3,079 incident colorectal cancer cases, including 1,121 with available tissue Bifidobacterium<\/em> data, during follow-up of 132,056 individuals. There was a difference in the association between long-term yogurt intake and colorectal cancer incidence based on the abundance of Bifidobacterium <\/em>(P heterogeneity = 0.0002). Multivariable-adjusted hazard ratios were 0.80 (95 percent confidence interval, 0.50 to 1.28) and 1.09 (95 percent confidence interval, 0.81 to 1.46) in individuals who consumed two or more servings\/week versus less than one serving\/month for Bifidobacterium<\/em>-positive and Bifidobacterium<\/em>-negative tumors, respectively. In a subgroup analysis of proximal colon cancer, this differential association was also seen (P heterogeneity, 0.018).<\/p>\n “Our findings suggest that long-term yogurt intake may lower the incidence of Bifidobacterium<\/em>-positive proximal colorectal cancer (but not Bifidobacterium<\/em>-negative subtype),” the authors write. “Further studies are warranted to elucidate the potential mechanisms for the effects of long-term yogurt intake on colorectal carcinogenesis.”<\/p>\n Two authors disclosed ties to the biopharmaceutical industry.<\/p>\n